BALL MEMORIAL HOSPITAL
- Type
- Teaching hospital
- Where
- MUNCIE, IN
- Medicare CCN
- 150089
- Received
- $190,070 in 74 records, 2019 ($4,010 general, $186,059 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: BALL MEMORIAL HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: BALL MEMORIAL HOSPITAL Fuzzy (name and state)
- Lobbying client: BALL MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 1 | $4,010 |
| 2019 | Research payment | 73 | $186,059 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| LivaNova USA, Inc. | 9 | $51,445 | 2019 |
| Amgen Inc. | 9 | $50,153 | 2019 |
| AstraZeneca Pharmaceuticals LP | 3 | $21,476 | 2019 |
| SANOFI US SERVICES INC. | 8 | $17,714 | 2019 |
| Boston Scientific Corporation | 23 | $15,390 | 2019 |
| Travere Therapeutics, Inc. | 6 | $13,273 | 2019 |
| CSL Behring | 10 | $9,711 | 2019 |
| Janssen Research & Development, LLC | 4 | $6,446 | 2019 |
| ZOLL Circulation Inc | 1 | $4,010 | 2019 |
| Novartis Pharmaceuticals Corporation | 1 | $450 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 73 | $186,059 |
| Gift | 1 | $4,010 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-21 | Amgen Inc. | $222 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-12-18 | Travere Therapeutics, Inc. | $608 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | 018CTXX15001 | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $660 | Research payment | Cash or cash equivalent | SQRX Pulse Generator Device, Tachy | S ICD PAS | 2019 |
| 2019-12-12 | CSL Behring | $1,254 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-10 | LivaNova USA, Inc. | $21 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-12-05 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-02 | LivaNova USA, Inc. | $952 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-12-02 | Boston Scientific Corporation | $370 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-11-18 | Boston Scientific Corporation | $517 | Research payment | Cash or cash equivalent | SQRX Pulse Generator Device, Tachy | S ICD PAS | 2019 |
| 2019-11-13 | AstraZeneca Pharmaceuticals LP | $9,156 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L | 2019 |
| 2019-11-13 | LivaNova USA, Inc. | $500 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-11-07 | Travere Therapeutics, Inc. | $5,293 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2019 | |
| 2019-11-07 | Travere Therapeutics, Inc. | $2,500 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2019 | |
| 2019-11-07 | Travere Therapeutics, Inc. | $1,795 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2019 | |
| 2019-11-07 | Travere Therapeutics, Inc. | $577 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2019 | |
| 2019-11-04 | Boston Scientific Corporation | $707 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART REGISTRY | 2019 |
| 2019-11-04 | SANOFI US SERVICES INC. | $500 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-10-22 | LivaNova USA, Inc. | $3,149 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-09-24 | Amgen Inc. | $10,198 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-09-23 | SANOFI US SERVICES INC. | $1,097 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-09-17 | LivaNova USA, Inc. | $1,035 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-09-17 | CSL Behring | $837 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-17 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-16 | Boston Scientific Corporation | $100 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-09-13 | Boston Scientific Corporation | $1,674 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-09-09 | Travere Therapeutics, Inc. | $2,500 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2019 | |
| 2019-08-26 | SANOFI US SERVICES INC. | $1,097 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-08-21 | LivaNova USA, Inc. | $9,328 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-08-13 | CSL Behring | $285 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-02 | Boston Scientific Corporation | $358 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART REGISTRY | 2019 |
| 2019-07-16 | LivaNova USA, Inc. | $32,187 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-07-11 | CSL Behring | $1,403 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-07-11 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-07-02 | SANOFI US SERVICES INC. | $650 | Research payment | Cash or cash equivalent | NO PRODUCT DISCUSSED Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-07-01 | Boston Scientific Corporation | $707 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART REGISTRY | 2019 |
| 2019-06-26 | Janssen Research & Development, LLC | $2,358 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) | 2019 | |
| 2019-06-19 | LivaNova USA, Inc. | $2,670 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-06-14 | Boston Scientific Corporation | $1,755 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-06-14 | Boston Scientific Corporation | $689 | Research payment | Cash or cash equivalent | SQRX Pulse Generator Device, Tachy | S ICD PAS | 2019 |
| 2019-06-14 | Boston Scientific Corporation | $75 | Research payment | Cash or cash equivalent | SQRX Pulse Generator Device, Tachy | S ICD PAS | 2019 |
| 2019-06-11 | CSL Behring | $4,680 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-06-11 | CSL Behring | $100 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-06-10 | Janssen Research & Development, LLC | $2,428 | Research payment | Cash or cash equivalent | A Randomized Double Blind, Placebo Group, Two-Arm, Multicenter study to Assess Efficacy of Canagliflozin on End Stage Ki | 2019 | |
| 2019-06-10 | SANOFI US SERVICES INC. | $1,097 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-06-10 | Amgen Inc. | $260 | Research payment | In-kind items and services | GALACTIC-HF | 2019 | |
| 2019-06-04 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-05-23 | Janssen Research & Development, LLC | $1,184 | Research payment | Cash or cash equivalent | A Randomized Double Blind, Placebo Group, Two-Arm, Multicenter study to Assess Efficacy of Canagliflozin on End Stage Ki | 2019 | |
| 2019-05-23 | Janssen Research & Development, LLC | $476 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) | 2019 | |
| 2019-05-23 | Novartis Pharmaceuticals Corporation | $450 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED 8 WEEK STUDY TO EVALUATE THE EFFECT OF LCZ696 VER | 2019 |
| 2019-05-22 | LivaNova USA, Inc. | $1,600 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-05-20 | Boston Scientific Corporation | $344 | Research payment | Cash or cash equivalent | SQRX PULSE GENERATOR Device, TACHY | S ICD PAS | 2019 |
| 2019-05-06 | Boston Scientific Corporation | $273 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART REGISTRY | 2019 |
| 2019-05-06 | Boston Scientific Corporation | $172 | Research payment | Cash or cash equivalent | SQRX PULSE GENERATOR Device, TACHY | S ICD PAS | 2019 |
| 2019-04-25 | AstraZeneca Pharmaceuticals LP | $11,299 | Research payment | Cash or cash equivalent | urvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung C | 2019 | |
| 2019-04-23 | AstraZeneca Pharmaceuticals LP | $1,021 | Research payment | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice dai | 2019 |
| 2019-04-22 | SANOFI US SERVICES INC. | $1,097 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-04-18 | Amgen Inc. | $2,964 | Research payment | In-kind items and services | GALACTIC-HF | 2019 | |
| 2019-03-19 | Amgen Inc. | $2,277 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-03-18 | SANOFI US SERVICES INC. | $8,166 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-03-18 | Boston Scientific Corporation | $3,510 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-03-18 | Boston Scientific Corporation | $1,059 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART REGISTRY | 2019 |
| 2019-03-18 | Boston Scientific Corporation | $506 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-03-18 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-03-18 | Boston Scientific Corporation | $85 | Research payment | Cash or cash equivalent | SQRX PULSE GENERATOR Device, TACHY | S ICD PAS | 2019 |
| 2019-03-02 | Amgen Inc. | $3,093 | Research payment | Cash or cash equivalent | GALACTIC-HF | 2019 | |
| 2019-02-19 | Boston Scientific Corporation | $344 | Research payment | Cash or cash equivalent | SQRX PULSE GENERATOR Device, TACHY | S ICD PAS | 2019 |
| 2019-02-04 | Boston Scientific Corporation | $270 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-01-29 | Amgen Inc. | $27,629 | Research payment | Cash or cash equivalent | GALACTIC-HF | 2019 | |
| 2019-01-28 | Amgen Inc. | $3,431 | Research payment | In-kind items and services | GALACTIC-HF | 2019 | |
| 2019-01-22 | Boston Scientific Corporation | $364 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART REGISTRY | 2019 |
| 2019-01-22 | Boston Scientific Corporation | $344 | Research payment | Cash or cash equivalent | SQRX PULSE GENERATOR Device, TACHY | S ICD PAS | 2019 |
| 2019-01-14 | SANOFI US SERVICES INC. | $4,010 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-01-01 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2019 | |
| 2019-01-01 | Amgen Inc. | $77 | Research payment | In-kind items and services | GALACTIC-HF | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Muncie, IN, county Delaware County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Muncie, IN | County Delaware County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 64,751 | 112,280 | 6,851,073 |
| Population, 2020 census P1 | 65,194 | 111,903 | 6,785,528 |
| Median age B01002 | 29.7 | 35.8 | 38.1 |
| Under 18 B01001 | 15.8% | 18.1% | 23.3% |
| 65 and over B01001 | 14.3% | 17.6% | 16.8% |
| Households B11001 | 26,479 | 46,256 | 2,716,009 |
| Foreign born B05002 | 3.3% | 2.5% | 6.3% |
| Median household income B19013 | $44,471 | $58,127 | $71,957 |
| Median family income B19113 | $60,880 | $74,407 | $90,767 |
| Per capita income B19301 | $25,281 | $31,091 | $38,351 |
| Poverty rate B17001 | 29.2% | 19.6% | 12.3% |
| Unemployment rate B23025 | 7.8% | 5.8% | 4.3% |
| Civilian labor force B23025 | 32,546 | 56,486 | 3,472,016 |
| Mean commute (minutes) B08013 | 18.1 | 21.2 | 24.1 |
| Bachelor's degree or higher B15003 | 26.1% | 26.2% | 29.5% |
| Housing units B25001 | 30,715 | 51,635 | 2,976,568 |
| Owner-occupied B25003 | 52.0% | 66.5% | 70.6% |
| Renters B25003 | 48.0% | 33.5% | 29.4% |
| Median home value B25077 | $97,300 | $139,400 | $218,200 |
| Median gross rent B25064 | $904 | $906 | $1,062 |
| White, not Hispanic B03002 | 78.4% | 84.3% | 75.4% |
| Black B03002 | 8.1% | 5.2% | 9.1% |
| Hispanic or Latino B03002 | 4.4% | 3.3% | 8.6% |
| Asian B03002 | 2.1% | 1.6% | 2.6% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Muncie, IN.
Comments